Deerfield Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Deerfield Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-300,000	Closed	-$42.5M	–	159
2021 Q2	$42.5M	Sell	300,000 -120,000	-29%	-$13.6M	0.75%	46
2021 Q1	$41.9M	Buy	420,000 +100,000	+31%	+$11.7M	0.88%	38
2020 Q4	$39.6M	Sell	320,000 -128,000	-29%	-$16.8M	0.78%	42
2020 Q3	$43.6M	Buy	448,000 +186,235	+71%	+$23.3M	1.06%	29
2020 Q2	$40.8M	Buy	261,765 +77,900	+42%	+$11.8M	1.19%	28
2020 Q1	$26.5M	Buy	183,865 +83,865	+84%	+$16.2M	0.84%	38
2019 Q4	$20.4M	Sell	100,000 -97,000	-49%	-$17.7M	0.65%	47
2019 Q3	$15.8M	Hold	197,000	–	–	0.64%	49
2019 Q2	$18.6M	Sell	197,000 -167,000	-46%	-$14.4M	0.67%	51
2019 Q1	$31.1M	Hold	364,000	–	–	1.19%	27
2018 Q4	$20.4M	Buy	364,000 +70,000	+24%	+$4.27M	0.82%	45
2018 Q3	$24M	Sell	294,000 -315,554	-52%	-$22.2M	0.86%	42
2018 Q2	$21.3M	Buy	609,554 +219,554	+56%	+$6.69M	0.75%	52
2018 Q1	$8M	Hold	390,000	–	–	0.28%	88
2017 Q4	$11M	Buy	390,000 +200,000	+105%	+$5.58M	0.43%	65
2017 Q3	$5.91M	Buy	+190,000	New	+$5.71M	0.27%	77

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Deerfield Management's RETA Position: Q3 2021 in Review

Deerfield Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 300,000 shares — an estimated $42.5M sold.

Deerfield Management first reported a position in RETA in Q3 2017 and held it in 16 quarters. The position peaked at $43.6M in Q3 2020. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

Deerfield Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
Deerfield Management sold 300,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $42.5M.
Deerfield Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 16 quarters.
Deerfield Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $43.6M in Q3 2020.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.